Monthly Archives: June 2020

Fat alternative Epogee gains traction: ‘The low-fat ship sailed 25 years ago, this is not about low fat, it’s about caloric reduction’ -…

Posted: June 13, 2020 at 12:45 am

Products already on the market containing Epogeeinclude enrobed caramel clusters and a fast-growing low-calorie ice cream brand delivering asuper-premium creamy mouthfeel,Epogee chief commercial officer Jayme Caruso told reporters in a briefing on Wednesday.

We have a customer about to launch a peanut spread and a chocolate hazelnut spread with EPG and we expect to see many more products hitting the market with EPG in the coming months.

EPG (esterified propoxylated glycerol) which be listed on food labels as EPG (modified plant-based oil) - can be used to replace up to 85% of the fat in scores of applications from confectionery to baking mixes, said Caruso, who said the FDA had just confirmed it had no objections to extending a GRAS determination for EPG to include potato chips, corn-based savory snacks, chicken nuggets, plant-based protein products, dairy analogs, and beverages/beverage bases.

To make EPG, the company splits rapeseed oil (although other vegetable oils can also be used) into glycerin and fatty acid, inserts a food-grade link, and reconnects them (see box below for details).

The modified fat (EPG) has a high melting point of 102F, which means that it doesnt liquify when it passes through the body (which typically has a temperature of around 98.6F) and has the consistency of soft candlewax, Caruso told FoodNavigator-USA.

It largely resists digestion because digestive enzymes are prevented from breaking it down, so hardly any of its calories are released, added Caruso, who is talking to potential partners from leading CPG brands to disruptive startups.

To put this into perspective, 1g of fat contains 9 calories, while 1g of Epogee contains 0.7 calories.

Unlike Olestra (which had a lower melting point and messy side effects) or fat replacers made from sugars, gums, starches or fibers (which provide bulking, humectancy and mouthfeel but many firms dont want to include on the ingredients list), EPG functions like fat in food products and in the human body because its made from fat, said Caruso.

In a nutshell, he said, EPG is unique in the food formulation space because its analternative fat, not a fat substitute EPG looks feels, tastes, and functions like fat because its made from fat, it just doesnt deliver the calories.

While fat reduction and replacement might have been all the rage in the 80s and 90s, consumers today some of whom are actively embracing high fat keto diets are more worried about sugar, acknowledged Caruso.

But theyre also worried about their weight, and they are still paying attention to calories, and given that fat contains a lot more calories per gram (9) than carbs or protein (4), it is the easiest target to drive calories out of products, he said.

The low-fat ship sailed 25 years ago, but this is not about low fat, its about caloric reduction.

And if food culture has undoubtedly changed since the technology behind EPGs was first developed three decades ago, most Americans are still consuming more calories than they are burning off, and many of them come from fat, added Caruso.

There is currently nothing like this is on the market. We have two products, a confectionery EPG with a very sharp melting curve designed to mimic cocoa butter or fractionated palm kernel oil, and our workhorse spreadable EPG, which works in all of the other applications.

As to whether EPG would be considered clean label, theres no simple answer as this is not a legally defined term, said Caruso, although he conceded that some natural and organic brands might not be interested.

However, brands that are trying to appeal to calorie-conscious consumers are particularly excited by Epogee's potential to cut calories but also eliminate ingredients such as gums, starches and binders, preservatives and flavor enhancers that are often used in low calorie or low fat foods, he said.

The road to commercialization has been lengthy for EPGs, which were first developed in the 1980s by ARCO Chemical Company, which teamed up with Bestfoods to explore their potential as fat replacers in foods.

However, Bestfoods withdrew from the joint venture shortly thereafter, and work did not resume until late 2003 when the technology was assigned to a non-profit affiliated with Kansas State University. A new partner, Choco Finesse, LLC, was later granted development rights and changed its name to Epogee.

'Not another Olestra'

Epogee is not anotherOlestra(a hybrid molecule of sucrose esterified with eight fatty acids from Procter & Gamble that attracted a wave of negative PR over its messy side effects... notably anal leakage), says founder and CTO David Rowe.

"We got to learn from their experiences and essentially avoid some things that they did but we also have better chemistry. Our product is safer in terms of things like vitamin depletion[Epogee does not inhibit the absorption of fat-soluble vitamins], but another key thing is that Epogee is made from fat and tastes like fat.

Olestra had kind of a weird mouthfeel and for people old enough to remember the potato chips, they didnt quite taste like potato chips, but French fries or donuts made with Epogee will actually beat regular French fries or donuts[on taste/mouthfeel].

What are EPGs?

EPGs are a family of fat- and oil-like substances that resemble triglycerides in structure and appearance, but have been modified to prevent or limit their digestion when consumed in food.

How is Epogee made?

*According to aGRAS noticesubmitted to the FDA in 2015, esterified propoxylated glycerol (EPG) is produced by a three-step process: First, fats and oils are split into glycerol and fatty acids. Next, glycerol is reacted with propylene oxideto produce glycerol with propyleneglycol units (PGUs) inserted on its hydroxyl groups. Finally, the propylene glycol-substituted glycerol is reacted with fatty acids to produce EPG, which largely resists digestion because the PGUs prevent the digestive enzyme lipase from breaking down the fat.

Is it safe?

The FDA has no questions regarding the GRAS status of EPG for multiple food applications including confectionery products; frying; baked goods and baking mixes; frozen desserts and mixes; nut products (including peanut butter); grain products; pasta; granola and snack bars; sauces and gravies; soft candy; snack foods (potato chips, corn-based savory snacks, chicken nuggets); plant-based protein products; dairy product analogs; beverages/beverage bases; coffee, and tea.

EPGs have been evaluated for safety at levels as high as 150 grams per day.

How is it labeled?

Epogee - the brand name for EPG (esterified propoxylated glycerol) can be listed on food labels as EPG (modified plant-based oil).

While the word modified might conjure up images of genetic engineering (which isnotinvolved in its production), Epogee has not experienced any pushback from manufacturers or consumers on the name, claimed Caruso, who noted that modified starch is a common term on food labels.

Read this article:
Fat alternative Epogee gains traction: 'The low-fat ship sailed 25 years ago, this is not about low fat, it's about caloric reduction' -...

Posted in Genetic Engineering | Comments Off on Fat alternative Epogee gains traction: ‘The low-fat ship sailed 25 years ago, this is not about low fat, it’s about caloric reduction’ -…

CRISPR-Based Therapeutics Market with Report In Depth Industry Analysis on Trends, Growth, Opportunities and Forecast – Cole of Duty

Posted: at 12:45 am

The orbisresearch.com has published CRISPR-Based Therapeutics market 2020 global trends and analysis report to its store

The Global CRISPR-Based Therapeutics market report is deep study of the present market dynamics. It consists of the detailed study of current market trends along with the past statistics. The past years are considered as reference to get the predicted data for the forecasted period. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry. A significant development has been recorded by the market of CRISPR-Based Therapeutics, in past few years. It is also for it to grow further. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry. A systematized methodology is used to make a Report on the Global CRISPR-Based Therapeutics market. For the analysis of market on the terms of research strategies, these techniques are helpful. All the information about the Products, manufacturers, vendors, customers and much more is covered in research reports.

Request a pdf sample at

https://www.orbispharmareports.com/sample-request/19996

Browse the full report at

https://www.orbispharmareports.com/global-crispr-based-therapeutics-market-2020-2026-report-by-type-applications-manufacturers-and-regional-overview/

Key Segmentation:

Key Players:Caribou BiosciencesAddgeneCRISPR THERAPEUTICSMerck KGaAMirus Bio LLCEditas MedicineTakara Bio USAThermo Fisher ScientificHorizon Discovery GroupIntellia TherapeuticsGE Healthcare Dharmacon

Types:Genome EditingGenetic EngineeringgRNA Database/Gene LibrarCRISPR PlasmidHuman Stem CellsGenetically Modified Organisms/CropsCell Line Engineering

Key Applications:Biotechnology CompaniesPharmaceutical CompaniesAcademic InstitutesResearch and Development Institutes

There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. There is a target set in market that every marketing strategy has to reach. The study is done with the help of analysis such as SWOT analysis and PESTEL analysis. SWOT analysis includes the study of Threats, weaknesses, strengths and opportunities that the CRISPR-Based Therapeutics market. Whereas PESTEL analysis is the study concerning Economic, Technological, legal political, social, environmental matters. For the analysis of market on the terms of research strategies, these techniques are helpful.

Have any inquiries on purchasing the report? If yes, then contact us @

https://www.orbispharmareports.com/enquiry-before-buying/19996

Potential consumers, market values, and the future scope for the CRISPR-Based Therapeutics market are explained thoroughly to the users in this report. The key players of CRISPR-Based Therapeutics industry, their product portfolio, market share, industry profiles is studied in this report. It is very important for the vendors to provide customers with new and improved product/ services in order to gain their loyalty. The study of various segments of the global market are also covered in the research report. In addition to that, for the forecast periods determination of factors like market size and the competitive landscape of the market is analyzed in the report. Due to the increasing globalization and digitization, there are new trends coming to the market every day. The research report provides the in-depth analysis of all these trends.

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

See the article here:
CRISPR-Based Therapeutics Market with Report In Depth Industry Analysis on Trends, Growth, Opportunities and Forecast - Cole of Duty

Posted in Genetic Engineering | Comments Off on CRISPR-Based Therapeutics Market with Report In Depth Industry Analysis on Trends, Growth, Opportunities and Forecast – Cole of Duty

Gene Therapy and Editing : Novel options for inherited retinal blindness – ETHealthworld.com

Posted: at 12:45 am

(Representative image) by Dr. Indumathi MariappanResearch Scientist, LV Prasad Eye Institute, Hyderabad

Retinal Blindness

Millions of people the world over suffer visual disability as a result of retinal dystrophy that involves the death of retinal cells that are important for the light sensing function of the eye. Enormous progress has been made in other blinding conditions involving the cornea, lens, among others. However, the retinal dystrophies and optic nerve atrophies do not have any proven therapy till date. The major forms of retinal dystrophies such as Age-related macular degeneration (AMD), retinitis pigmentosa (RP), Lebers congenital amaurosis (LCA), Stargardts disease etc. are either inherited disorders or developed with aging. In most cases, the retinal cells are present at birth, but undergo gradual death during the later stages of life. It is typically characterized by initial symptoms of low vision and night blindness during early childhood, which progresses to severe visual impairment and total blindness at different stages of adulthood. Inherited defects in many genes involved in retina-specific functions and vitamin A metabolism are linked to various forms of retinal dystrophies. These genetic defects affect the normal cellular functions of the retina, leading to gradual cell death and ultimately the patient becomes legally blind.

Recent Technologies and Novel Treatment Options

The current modalities for the treatment of such patients mainly include dietary supplements, visual aids and rehabilitation support. However, a radical approach is required either to preserve or to restore visual function in these patients. Some of them include the replacement of either the lost retinal cells or the defective genes within the surviving, but non-functional retinal cells. This has been the principle behind the massive efforts involved in the development of cell and gene-based therapies. They are currently at different stages of product development and clinical trial evaluation. In cell therapy, normal retinal cells are prepared from specialized stem cells and are injected into the eye to replace the lost cells and to restore retinal functions. Clinical safety trials using cell therapy are ongoing in many countries such as USA, Japan, UK and others (Weblinks 1-4). In gene therapy, the prime strategy is to introduce a normal copy of the affected gene into the surviving retinal cells of the patient, to restore normal cellular functions and improvements in vision. This is achieved by engineering safe viral vectors to carry a normal copy of the desired gene as their cargo. When injected into the eye, the viruses can infect the retinal cells once and deliver the normal gene to restore cellular functions (Weblinks 5-7). A step further is an advanced method of DNA microsurgery, wherein, the defective part of the retinal cell DNA is precisely edited to correct the genetic defect and to restore cellular functions. This could be achieved using the latest gene editing tools such as ZFNs, TALENs, CRISPR/Cas systems etc. These are naturally occurring molecular scissors, employed as host defense mechanism and immune memory to combat viral infections in different species of bacteria. These systems are now engineered to enable DNA and RNA editing in almost any living cells. Such tools are now combined with either cell therapy or gene therapy to develop novel drugs for the treatment of various inherited genetic diseases (Weblink 8).

Gene therapy products approved for clinical use:

LUXTURNATM (Weblink 5)

This is the first commercial gene therapy drug approved by the US-FDA and European Commission for the treatment of an early childhood retinal dystrophic condition called the Leber Congenital Amaurosis 2 (LCA2). This disease is caused due to genetic defects in the gene called RPE65. LUXTURNA (AAV2-hRPE65v2 or Voretigene neparovec-rzyl) is an engineered adeno-associated virus 2 (AAV2) vector carrying a normal copy of the human RPE65 gene. This product was developed and marketed by Spark Therapeutics, a US-based startup now owned by Roche, a Swiss pharma company.

This drug has been tested on 20 patients, aged 3 years or older, in a randomized, controlled, open label, phase 3 interventional clinical trial at two sites in the US from June 2015. All treated individuals showed significantly improved functional vision, with no product-related serious adverse events or deleterious immune responses. The treated patient will be followed for further 15 years until March 2030 to assess the long-term retinal gene expression and stable maintenance of functional vision. It is administered as a onetime injection behind the retina of an eye of patients genetically diagnosed to carry mutations in RPE65 gene and also have sufficient viable retinal cells. It is priced at $850,000 for two eyes in the US and UK, which translates to about 6.5 crores in Indian rupees.

Many such gene therapy vectors are currently under clinical trial evaluation for the delivery of other retinal gene such as REP1, PDE6B, RPGR, OAT (Ornithine aminotransferase), MERTK, sFLT1etc.

EDIT101 (Weblink 8)

This is the first gene editing based drug approved by US-FDA, for the treatment of another early childhood retinal dystrophic condition called LCA10, caused by defects in the CEP290 gene. Here, it is important to understand that a gene editing approach is different from a gene therapy. In gene therapy, a normal copy of entire gene is delivered to the retina to complement the defective gene. In CRISPR/Cas9 based gene editing, only the mutated region of the gene is edited/corrected in situ inside the target cells. This is an attractive approach for correcting a variety of gene mutations, especially those in large genes which exceed the cargo capacity of the commonly used AAV-based gene therapy vectors.

EDIT101 (AGN-151587) is an engineered adeno-associated virus 5 (AAV5) vector carrying a CRISPR/Cas9 based DNA editing machinery to locate and remove a specific mutation hotspot within the intron 26 of human CEP290 gene. When injected behind the retina, the virus will infect the surviving photoreceptor cells and deliver the CRISPRs to enable mutation editing. Successful DNA edits in photoreceptor cells would inactivate a spurious splice site created by the mutation and restore normal protein expression and retinal function.

Preclinical testing in mice and monkey eyes has proved significant edit efficiency of up to 28%, which was above the expected 10% threshold required for clinical efficacy in human trials. This drug was developed by the gene editing company, Editas Medicine, Inc. and is being tested in 18 participants in a Phase 1/2 clinical trial sponsored by Allergan, at four sites in the US from March 2019 and the outcomes are awaited.

Similar gene editing strategy is being explored at different centers for mutation correction in other retinal genes such as KCNJ13, RP1, USH2A, MYO7A, RDH12 etc.

Who can benefit?

Both gene therapy and gene editing approaches have opened up newer hopes for the treatment of various genetic condition affecting different cell types of the body. However, only a small subset of patients can benefit from such therapies at the moment. Such treatment considerations require a thorough genetic screening/genotyping to confirm the identity of the gene affected in a specific patient. Further, the patients should retain some viable cells in the retina for the treatment to be clinically effective.

Research efforts in India

Many labs in the country are developing gene therapies and gene editing based therapeutics for the treatment of various diseases affecting the blood, retina, liveretc. Researchers at the CMC, Vellore, CSIR-IGIB, Delhi, CSIR-CCMB, Hyderabad are developing gene therapeutics for the treatment of different forms of blood disorders. Narayana Nethralaya, Bangalore is engaged in developing AAV-based gene therapies for various retinal dystrophies. Our lab at the LV Prasad Eye Institute is collaborating with the research teams at IIT-Kanpur and CSIR-IGIB, Delhi to develop modified gene therapy vectors for retinal gene delivery and cell-based therapies using CRISPR edited stem cells and retinal cells respectively.

The way forward

As of May 2020, the RetNet database lists about 271 genes to be associated with different forms of retinal dystrophies. This requires a larger library of gene delivery vectors to be developed and made available at affordable costs for the treatment of a large number of patients. This mandates the need for developing indigenous and cost-effective therapeutics and ICMR has set up a dedicated task force on gene therapy research, to identify and support promising research ideas in this newly emerging area of biomedical research. A national guideline for gene therapy product development and clinical trials has been jointly formulated and released by the DBT and ICMR in 2019. It is hoped that the streamlined regulatory framework would fast track our basic and translational research efforts into developing novel and cost-effective treatment options in the near future.

Read this article:
Gene Therapy and Editing : Novel options for inherited retinal blindness - ETHealthworld.com

Posted in Genetic Engineering | Comments Off on Gene Therapy and Editing : Novel options for inherited retinal blindness – ETHealthworld.com

Fat cells remember their diets early in life – Massive Science

Posted: at 12:45 am

Our relationship to Neanderthals has been a point of contention for over a century. It all began with an inaccurate reconstruction of the first Neanderthal ever found, which portrayed them as brutish, stooped-over cavemen (turns out, that Neanderthal was an injured old man with arthritis).

But within the last half century, scientists have noticed the many biological and behavioral similarities that show just how close our species are. While these similarities are clear from hard objects like bones and tools, perishable objects, which comprise the majority of material culture items in humans, have been lacking.

Now, scientists have discovered a Neanderthal feat that hammers another nail in the coffin of supposed Neanderthal inferiority. Last month, an international team of researchers found a small section of a twisted cord attached to a stone flake in Neanderthal site in southeastern France, dated to over 40,000 years old. This constitutes the oldest direct evidence of fiber technology ever found.

A stone flake with three distinct twisted fibers preserved (indicated by the box).

M.-H. Moncel

When artifacts are recovered from archaeological sites, they are generally imaged using high powered microscopes to zoom in on tiny marks and details on the stones. Previously, plant fibers had been found on stones at this site, but they were too poorly preserved to be interpreted. When the team examined this particular flake, they were surprised to find three distinct twisted fibers, which were then twisted together in the opposite direction to form a 3-ply cord.

While it may not sound like much, this piece of string hints at something much more significant. For one, extracting and manipulating plant fibers requires working memory, as well as understanding plant seasonality and the concept of numbers. Also, such cords are the building blocks for creating other textiles, such as baskets, fabrics, and nets. Once adopted, these objects would have been indispensable in daily life.

This little piece of string provides unprecedented insight into the lives of our extinct relatives, which, despite an abundance of genetic, archaeological, and skeletal data, have been extremely difficult to interpret. It seems as though we humans arent as unique as we like to think.

Read more:
Fat cells remember their diets early in life - Massive Science

Posted in Genetic Engineering | Comments Off on Fat cells remember their diets early in life – Massive Science

New Survey Reveals 74 Percent of Americans are Concerned that Vitamins and Supplements are not Backed by Trustworthy Research – PRNewswire

Posted: at 12:44 am

FORT LAUDERDALE, Fla., June 10, 2020 /PRNewswire/ --When it comes to choosing the right vitamin, 74 percent of Americans are concerned that the advertised or promised benefits of vitamins and supplements are not backed by trustworthy research. As Americans begin to focus more on overall health and wellness, Life Extension, the health solutions expert translating scientific research for over 40 years into premium, clinically studied vitamins and supplements, wants to help consumers take away the guesswork when selecting the right vitamins and supplements to maintain their whole health, self-care.

To highlight the importance of choosing the best options, a new survey conducted by Life Extension revealed there is a clear crisis in confidence with Americans when it comes to their vitamin and supplement options. While nearly all supplement users (92 percent) believe that ingredients are important when purchasing a vitamin, two-fifths (42 percent) do not research the ingredients when considering which product to choose.

"Better health and quality of life are the biggest motivators when taking vitamins and supplements, but unfortunately, many people don't know where to start and how to find a trusted resource," said Michael Smith, MD and Life Extension Education Director. "That's why at Life Extension we make it easy to find high quality, research-backed vitamins and supplements. We offer free Wellness Specialists to answer questions prior to taking a vitamin or supplement and laboratory panel testing to help personalize supplement choices."

Additional survey highlights include:

The survey found that while Americans want their vitamins to work, they are not putting in the work to find the right ones for them. Roughly three-quarters of supplement users do not research factors that determine or contribute to the overall effectiveness of the products they are spending their money on, such as third-party testing (75 percent), industry certifications (73 percent) or where the product is made (72 percent). Life Extension researches, test and retest every ingredient in all of their products, and pride themselves on their quality clinical research to substantiate ingredient benefits and the efficacy of their formulations. Constant scrutiny of published scientific findings is used to establish optimal dosages for maximum benefit.

Find out more about the Vitamin and Supplement Buyer Confidence and Knowledge Survey

Survey Methodology

These highlights present the findings of an online survey conducted among a nationally representative sample of 1,500 Americans 18 years of age and older, who live in the United States and take a vitamin or supplement at least 2-3 times a week. The total sample data is nationally representative based on age, gender, ethnicity, region, household income and educational attainment. The online survey was conducted by Lucid and completed between January 28th and February 4th, 2020. The margin of error for the total sample at the 95% confidence level is +/- 2.53 percentage points.

About Life Extension

Life Extension is the health solutions expert that is translating scientific research into everyday insights for people wanting to live their healthiest lives. For nearly 40 years, Life Extension has pursued innovative advances in health, conducting rigorous clinical trials and setting some of the most demanding standards in the industry to offer a full range of quality nutritional vitamins and supplements and blood-testing services. Life Extension's Wellness Specialists provide personalized counsel to help customers choose the right products for optimal health, nutrition and personal care. To learn more, visit LifeExtension.com.

SOURCE Life Extension

https://www.lifeextension.com

See the original post here:

New Survey Reveals 74 Percent of Americans are Concerned that Vitamins and Supplements are not Backed by Trustworthy Research - PRNewswire

Posted in Life Extension | Comments Off on New Survey Reveals 74 Percent of Americans are Concerned that Vitamins and Supplements are not Backed by Trustworthy Research – PRNewswire

Maintaining health and nutrition while staying at home – WSAW

Posted: at 12:44 am

(WZAW) -- The disruption to everyday life has impacted our mental and physical health. Focusing on ones health is more important than ever, and now is the right time to evaluate and improve your diet and learn more about what vitamins and supplements are needed and where to get them.

A new survey conducted by Life Extension reveals 39% of American supplement takers are motivated to take vitamins because they believe their diet is lacking and vitamins and/or supplements help them make up for it, but while nearly 92% of the users believe the ingredients are important when purchasing, 42% dont research the ingredients when considering which product to choose. Additionally, many respondents 74% are concerned the benefits of supplements are not backed by trustworthy research.

On Tuesday, registered dietitian Maya Feller joined NewsChannel 7 at 4 to share tips to help Americans live their healthiest lives, including supplement recommendations for specific deficiencies.

The best ways to get your nutrients from food is to really look to foods that are in whole or minimally processed form. So, things like fruits, vegetables, whole grains, with limited added sugars, salt and synthetic fat, Feller explained. Its going to give your body a plethora of access to vitamins and minerals.

If you arent eating those foods, Feller said its important to fill those nutrient gaps. Thats when you can introduce supplements.

When were thinking about supplementation, safe supplementation is key.

She said people can learn if a nutrient or supplement is right for them by is to get a lab test done.

They can go to lifeextension.com and request a lab panel right there. They can then take that result back to a Life Extension wellness expert, or they can take it to their primary care provider or dietician, Feller explained. That way the supplementation can really be individualized, so that people are taking the correct dosage at the right frequency in intervals over the right period of time.

See the original post:

Maintaining health and nutrition while staying at home - WSAW

Posted in Life Extension | Comments Off on Maintaining health and nutrition while staying at home – WSAW

Why a decision on a second US plutonium-pit-production factory should be delayed – Bulletin of the Atomic Scientists

Posted: at 12:44 am

The troubled Mixed-oxide Fuel Fabrication Facility project at the Savannah River Site is proposed to be transformed into a plutonium pit production facility. Photo (c) Timothy Mousseau, 2019.

The National Nuclear Security Administration (NNSA), the organization within the Energy Department that is responsible for producing and maintaining US nuclear warheads, is moving forward with a plan to build a plutonium-pit-production factory at DOEs Savannah River Site in South Carolina. Pits are the form of the plutonium in the fission trigger primaries of US two-stage nuclear warheads.

The primary motivation for this move is lack of confidence in the pit-production capacity at Los Alamos National Laboratory, which has been responsible for preserving US pit production expertise since production at the Rocky Flats Plant outside of Denver shut down at the end of the Cold War. There are also political motivations, including filling the jobs gap at the Savannah River Site resulting from the collapse of NNSAs effort to build a Mixed-oxide Fuel Fabrication Facility there to process some of its excess Cold War plutonium pits into power reactor fuel.

NNSAs rush forward may result in a debacle on top of a debacle. If the experts at Los Alamos cant manage pit production there, why does NNSA think that they can design and train the staff to operate a pit-production facility at the Savannah River Site?

Also, the United States need for pits is unclear at the moment. In 2007, the pits produced at Rocky Flatsnow 30 to 40 years oldwere pronounced to be good for at least a century and, in 2012, the Lawrence Livermore National Laboratory upped the durability estimate to 150 years. NNSA did not support the necessary research to solidify this conclusion, howeveran oversight that it now promises to remedy.

The NNSA also claims that it needs to produce new pits for two types of safer primaries for two new nuclear warheads, but there seem to be enough already-existing pits for one of the warheads, and the design for the second has not yet been decided.

Thus, there are multiple arguments for delaying a decision on the proposed second pit-production facility for a decade or so. By then, Los Alamos should have mastered the production of pits, the longevity of the legacy pits will be better established, and the need for pits not available in the legacy stockpile should be clarified.

Pits, the critical components. Each US nuclear warhead contains a miniature advanced version of the Nagasaki nuclear bomb weighing only about two percent of what the original Nagasaki bomb weighed. This primary is built around a hollow shell of plutonium, which is surrounded by chemical explosive.

If that explosive is triggered, the pit will be imploded rapidly into a spherical solid mass compressed to perhaps twice the normal density of plutonium. Near the point of maximum density, before the plutonium begins to bounce back to its normal density, a small neutron generator will spray it with a burst of neutrons that will initiate exponentially multiplying fission chain reactions. Within a microsecond, about 20 grams of the plutonium will fission, releasing energy equivalent to the explosion of about 300 tons of TNT, heating the material in the primary to about a million degrees Centigrade.

At that temperature, fusion reactions will occur in the several grams of tritium and deuterium that were injected into the hollow pit just before the implosion. Those fusion reactions will produce an intense burst of neutrons that fission hundreds more grams of plutonium, boosting the energy of the fission explosion to the equivalent of about 10,000 tons of TNT, half the power of the Nagasaki bomb.

At that point, the primary will be so hot that its glow will be mostly X-rays that will fill the radiation case surrounding the primary and a secondary nuclear explosive nested next to it. The X-rays will vaporize the outer layer of the secondary, imploding and heating it and igniting a mix of fusion and fission reactions that, depending on the warhead, will release from a few times to 25 times the energy of the Nagasaki bomb from a warhead about one-twentieth the weight of the 4.4 ton Nagasaki bomb.

Will aging pits still work? The last nuclear test of a US primary was conducted in 1992, when Congress imposed a moratorium on US nuclear testing, launching negotiations on the Comprehensive Test Ban Treaty, which the United States signed in 1996. The treaty has not come into force because eight countries, including the United States, have not ratified it; nevertheless, it appears to have moral if not legal force. No country other than North Korea has tested a nuclear weapon since 1998, and North Korea stopped in 2017.

Despite the lack of US testing, there is no doubt that the primaries in US nuclear warheads will implode or that, if the primary works, the secondary will explode. The issues that have been raised relate to whether the plutonium might become brittle and fragment as it implodes, and whether, if that happened, the tritium-deuterium boost gas would ignite. The NNSA spends billions of dollars each year investigating this question with ever-more-refined computer simulations of what happens inside a pit during its implosion and tests of the behavior of aging plutonium under shock, including in subcritical tests in tunnels deep under the former Nevada Test Site.

Every year, the three NNSA weapon labsLivermore, Los Alamos, and Sandiaand the US Strategic Command, which would deliver most US warheads in a nuclear war, go through an elaborate review process of the condition of the warheads and of the simulations, including by red teams of skeptics, before they certify to Congress, via the secretaries of Defense and Energy and then the president, that they are confident the warheads would work and that no tests are required.

During the Cold War nuclear arms race, pits and other weapon components were replaced regularly as one generation of nuclear weapons succeeded another. That evolution stopped with the end of nuclear testing. Today, most of the US warheads have undergone or are going through a life-extension process, with most components being replaced. The pits themselves are not yet being replaced, however. The United States has not been making new pits in significant numbers since 1989 when the FBI and Environmental Protection Agency raided the Energy Departments pit production plant at Rocky Flats outside Denver for environmental crimes. The plant was subsequently razed. (See former Bulletin editor Len Acklands 1999 book, Making a Real Killing: Rocky Flats and the Nuclear West.

That the US is not able to replace the pits has become a perennial point of anxiety for the US nuclear-weapon establishment and its congressional overseers. Proposals have been made, but no new pit production facilities have been builtin part because the pits made by Rocky Flats have proven remarkably durable. They are sealed and plated, and they have suffered virtually no corrosion. The main question is whether the emission of alpha particles (helium nuclei) by the slow decay of the plutonium is changing the mechanical properties of the material.

In 2005, Congress directed the NNSAs administrator to commission an independent review of the efforts at the Los Alamos and Lawrence Livermore laboratories to estimate pit lifetimes. The review was carried out by JASON, a group of experts, mostly academics, who do summer studies on issues of interest to the Defense and Energy departments. An unclassified summary of the groups findings was released in early 2007.

Los Alamos and Livermore had been analyzing the effects of plutonium aging on the functionality of US pits. They also had been doing accelerated-aging experiments on samples of the plutonium alloy used in US pits by spiking them with plutonium-238, which decays by alpha emission with a half-life of 88 years, versus the 24,000 years for the dominant isotope in weapon-grade plutonium, Pu-239.

The summary conclusion of the 2007 JASON report was:

We judge that the Los Alamos/Livermore assessment provides a scientifically valid framework for evaluating pit lifetimes. The assessment demonstrates that there is no degradation in performance of primaries of stockpile systems due to plutonium aging that would be cause for near-term concern regarding their safety and reliability. Most primary types have credible minimum lifetimes in excess of 100 years as regards aging of plutonium; those with assessed minimum lifetimes of 100 years or less have clear mitigation paths that are proposed and/or being implemented.

The JASON report also recommended additional research (pp. 17-18):

to gain experience with Pu that has suffered the equivalent of a century or more of aging (i.e., with accelerated aging), thereby allowing an interpolation rather than an extrapolation in estimating performance changes and degradation due to aging. In particular, one wants to know the modes of failure that will be among the first to appear, because these can inform the stockpile surveillance program in order to make it most sensitive to aging-induced degradation [and] ongoing study of the current accelerated-aging Pu samples, which are spiked with the rapidly-decaying 238Pu, as well as production of samples that have been aged by alternative means. In all of these cases, the objective is to get the equivalent of multi-century experience on aging phenomena, associated with decay (e.g., radiation damage) as well as with activated processes such as annealing.

Some work on accelerated aging did continue and, in 2012, the Livermore lab reported, no unexpected aging issues are appearing in plutonium that has been accelerated to an equivalent of ~ 150 years of age.

Livermores deputy program leader for enhanced surveillance of pit aging stated, In the near term, the nation can save tens of billions of dollars that might be required to build a new production facility.

Pit-production problems at Los Alamos. In 1999, to maintain US pit-production expertise, the Energy Department instructed Los Alamos to establish pit production capacity of up to 20 pits per year within its large PF-4 plutonium facility. Surprisingly, however, despite the history of Rocky Flats having routinely produced 1,000 to 2,000 pits per year, Los Alamos has struggled to produce a small number of pits, even though the lab has spent billions of dollars on pit-production efforts.

In 1996, the Energy Department tasked Los Alamos to produce 31 war reserve pits for the W88, the high-yield warhead for US ballistic missile submarines, for an order that had not been completed because of the shutdown of the Rocky Flats plant. It took 16 yearsuntil 2012to fabricate the pits. Eleven were produced in 2007 but then a declining number annually thereafter.

The plan was to transition to producing pits for additional W87 warheads for the US Minuteman III intercontinental ballistic missile. In 2013, however, pit production at Los Alamos was shut down because of inadequate worker safety training and concerns about potential plutonium criticality accidents. Seven years later, pit production is still shut down at Los Alamos and the expectation is that this situation will continue until 2023.

NNSAs budget submission for fiscal year 2021 states that Los Alamos is engaged in activities to hire, train, qualify, and retain required pit production personnel, recapitalization of equipment needed to restore Plutonium Facility (PF)-4s ability to produce War Reserve (WR) [pits,] towards producing the first WR pit during 2023 [and] manage capital acquisitions to increase production capability of PF-4 to produce 10 pits per year.

The cost of the planned upgrades to PF-4 is estimated at $1.75 billion through fiscal 2025.

Eighty pits per year? In 2008, the departments of Defense and Energy decided that the United States needed a pit production capacity of 50 to 80 pits per year. This range was based on the very rough computation that it would take 30 to 90 years to replace the pits in a US stockpile of 2,500 to 4,500 warheads at that rate. It was assumed that the production could be carried out at Los Alamos.

But Los Alamos continued to flounder. In 2014, Congress backed the goal of 50 to 80 pits per year with a sense of Congress statement (which does not have the force of law) backing a requirement of a production capacity of 30 pits per year by 2026 and a demonstration over 90 days during the following year of a production rate of 80 pits per year. In 2019, the date of that goal slipped to 2030, but, in the Defense Authorization Act of 2020, Congress added the message that any further delay to achieving a plutonium sustainment capability to support the planned stockpile life extension programs will result in an unacceptable capability gap to our deterrent posture.

The Trump administrations 2018 Nuclear Posture Review which also does not have the force of law turned these various assertions into a requirement for an enduring capability and capacity to produce plutonium pits at a rate of no fewer than 80 pits per year by 2030.

Two pit production facilities? After an initial expenditure of $7 billion on construction of a Mixed Oxide Fuel Fabrication Facility at the Savannah River Site to fabricate excess Cold War plutonium into reactor fuel, the cost continued to grow: It was estimated that the cost to completion of that NNSA project had climbed to $30 billionfor a program that Congress had originally been told would cost $2 billion. Congress voted to shut the project down and, in early 2018, the Trump Administration agreed, raising the question of what to do with the fortress structure that had been built and how to compensate the South Carolina delegationespecially its powerful leader, Sen. Lindsey Grahamfor the loss of jobs the cancellation of the MOX plant entailed.

In this context, the idea was born to divide the pit-production mission between Los Alamos and Savannah River.

In 2018, the Defense Department and the NNSA issued a joint statement asserting that there would be two pit-production facilities: one at Los Alamos producing at least 30 pits per year and one at Savannah River producing at least 50 pits per year. In this way, the 2008 goal of demonstrating a production capability of 50 to 80 pits per year at Los Alamos had 10 years later become a minimum combined production rate of 80 pits per year at Los Alamos and Savannah River.

Updating the pit durability estimate. Meanwhile, the question remained as to what a decade of additional research at Los Alamos and Livermore had revealed about the lifetimes of the legacy pits.

In March 2018, the Senate Appropriations Committee, in its report on the Energy and Water Appropriations Act for fiscal 2019, directed the NNSA administrator to contract with JASON to do an update on its 2007 report on expectations for the longevity of the Rocky Flats legacy pits. The instruction was that JASON should be contracted to assess the efforts of the NNSA to understand plutonium aging and the lifetime of plutonium pits in nuclear weapons [and] include recommendations of the study for improving the knowledge, understanding, and application of the fundamental and applied sciences related to the study of plutonium aging and pit lifetimes, an estimate of minimum and likely lifetimes for pits in current warheads, and the feasibility of reusing pits in modified nuclear weapons. The report shall be submitted in unclassified form but may include a classified annex.

The Senate instructed the NNSA administrator to make available all information that is necessary to successfully complete a meaningful study on a timely basis.

A year and a half later, in November 2019, after a near-death experience at the hands of the Trump administration, JASON submitted a three-page letter report informing Congress that it could not update its previous estimate because, in general, studies on Pu aging and its impacts on the performance of nuclear-weapon primaries have not been sufficiently prioritized over the past decade. A focused program of experiments, theory, and simulations is required to determine the timescales over which Pu aging may lead to an unacceptable degradation of primary performance.

The JASON letter also suggested that, contrary to Congresss instruction, NNSA had not cooperated adequately with the review: The labs briefly presented their program to address Pu aging to JASON. The plan seemed sensible, but a detailed JASON assessment would require additional information about the program as well as technical details.

Laudably, NNSA was embarrassed and, in April 2020, administrator Lisa E. Gordon-Hagerty informed the chairman of the Senate Armed Services Committee Subcommittee on Strategic Forces that her agency planned to fund a second phase of the JASON study during the summer of 2020 to [a]ssess the need for the full study, and if deemed necessary and timely, perform a more detailed, multi-year JASON study.

The letter also stated that NNSA has launched an enhanced program focused on understanding the potential effects of plutonium radioactive decay, or aging, on pit performance.

Other needs for new pits? In addition to the potential need to replace pits because they are aging, NNSA also is advocating the new production facility to produce pits with enhanced safety features to meet NNSA and DoD requirements.

This quest goes back 30 years, to the launch of the Stockpile Stewardship Program by the Clinton Administration. At the time, the weapon labs proposed to replace the W78 ICBM warhead and the W76 and W88 submarine-launched ballistic missile (SLBM) warheads with new warheads containing insensitive high explosive. That proposal has been sustained over the decades since through a number of incarnations, including proposals for warheads that would be interoperable between the ICBMs and SLBMs.

The purpose of insensitive high explosive is not to reduce the probability of an accidental nuclear explosion. Other elements of the safety design are supposed to do that, and, to date, no warhead accident has resulted in a nuclear yield.

The benefit from the use of insensitive high explosive would be to reduce the number of accidents in which the chemical explosive around a pit is detonated and plutonium is dispersed. There were many such accidents involving aircraft-carried warheads prior to the decision not to fly nuclear-armed aircraft in peacetime. The most famous was the collision of a nuclear-armed B-52 strategic bomber with its refueling tanker over Spain in 1966, which resulted in a large area of plutonium contamination on the ground, requiring 1,600 US military personnel to be deployed for up to 12 weeks, working with minimal protection, gathering contaminated dirt and crops into barrels for shipment back to the US for burial on the Savannah River Site. The Navy has had no such accidents with its SLBM warheads, however, and believes that reducing the risk significantly would require redesigning its Trident missile as well as their warheads. It therefore has in the past not been willing to invest in adapting new insensitive high explosive warheads to its missiles, a process that would include flight tests.

It appears, however, that the Navy has finally acquiesced or been overruled on this matter, and the plan is to replace its two SLBM warheads, the W76 and W88, with new warheads that use insensitive high explosive.

The current proposal is to build two new warheads. The first is the W87-1, which would replace the W-78 on the Ground-Based Strategic Deterrent, the successor to the Minuteman III missile, and potentially also the W-88, the high-yield warhead on the Trident II submarine-launched ballistic missile. A second warhead, sometimes referred to as the W93, would replace the W76.

The pit of the W87-1 would be identical to the pit of the W87-0, which is currently deployed on the Minuteman III, and is to be used on the Ground-based Strategic Deterrent. The 400 Minuteman IIIs are to be replaced one-for-one with the new ICBM, which, like the Minuteman III, is to be deployed with only a single warhead per missile.

The Defense Department reportedly has 540 W87-0s in stock, of which 200 are deployed on the Minuteman III along with 200 W78s. Therefore, the W78s could be replaced with stored W87s. The department wishes, however, to preserve the option of loading more warheads onto the new Ground-Based Strategic Deterrent, in case of a breakdown in nuclear arms control with Russia. This has been called a warhead upload hedge since the Clinton administration. To load up 400 of the new missiles with three warheads each would require 1200 warheads, which would require more W87-1s and therefore more pits.

No realistic circumstance that would require uploading the US ICBMs has been suggested, however. The Joint Chiefs reportedly informed President Obama that they could cover all essential targets in potential adversary nations with one third fewer warheads than the 1,550 counted warheads that are allowed by New START. Further, Minuteman IIIs were downloaded to one warhead each after the end of the Cold War to make the deterrent relationship with Russia more stable. After the downloading, destroying one US warhead in a first strike would, on average, require more than one Russian warhead.

Beyond those arguments against uploading, many respected defense experts, including former Defense Secretary William Perry, argue that the US should abandon fixed land-based ICBMs altogether, because Strategic Command insists on keeping them in a dangerous launch-on-warning posture.

Little firm information has been made public about the design of the proposed W93 warhead for submarine-launched nuclear missiles. In fact, NNSAs Fiscal Year 2020 Stockpile Stewardship and Management Plan describes the Next Navy Warhead, as not yet an established program of record.

An anonymous senior defense official has offered the reassurance, however, that the W93 would be previously nuclear-tested designs, its not going to require any nuclear testing. This must mean that a previously tested insensitive high explosive primary would be used.

In 1990, in hearings before the Senate Appropriations Committees Subcommittee on Energy and Water, the Energy Departments then Deputy Assistant Secretary of Energy for Military Applications listed all US nuclear warheads with insensitive high explosive, including warheads that had been produced and deployed and some that had been tested but not deployed as a result of the end of the Cold War. The candidate warhead that has been discussed for three decades is the W89, one of the warheads that was tested but not produced. The W89 was to use recycled pits. According to one report, the pits were to be from the W68, a previous-generation SLBM warhead for which thousands of pits were produced during the 1970s. If that option were pursued, and the W68 pits were found to be still functional, no new pit production would be required.

The decision on the second pit production facility can wait. NNSA could announce its decision to move forward on building a pit-production facility in South Carolina as early as September. Based on the above context, this decision should be delayed for a number of reasons:

1. Since the Savannah River Site staff has no experience with pit production, the facility would have to be designed and the staff trained by the Los Alamos group. But the Los Alamos group has not yet demonstrated that that it can design and staff its own pit production facility.2. Within a decade, we should have a new lower limit on the functional lives of the legacy pits. If they will indeed last for at least 150 years, as the Livermore experts concluded, then there will be no need for a large production facility to replace them anytime soon. The Los Alamos facility, if it can be made operational, should be sufficient for some decades.3. The argument for producing additional warheads with insensitive high explosive for the Minuteman III replacement is very weak, and the debate over the need to produce new pits for a warhead to replace the W-76, the most numerous warhead in the US operational stock (about 1,500) cannot be made until NNSA and Defense Department are ready to discuss what pit they would use in the W93.

We can wait for another decade before we decide on whether the United States requires two pit production facilities. Indeed, we can wait for another decade before we decide on whether we need any new pits at all.

See original here:

Why a decision on a second US plutonium-pit-production factory should be delayed - Bulletin of the Atomic Scientists

Posted in Life Extension | Comments Off on Why a decision on a second US plutonium-pit-production factory should be delayed – Bulletin of the Atomic Scientists

The Role Of Nuclear Power In A Clean Energy System – Seeking Alpha

Posted: at 12:44 am

In the case of nuclear fade, the European Union sees the most significant decline in capacity in absolute terms at over 100 GW. Of the 126 reactors in operation, 89 are set to be decommissioned by 2030 without further extensions. By 2040, just 15 of the existing reactors are still in operation, complemented by four reactors that are under construction. The fade will most impact publicly traded utilities in Germany and Scandinavian countries, but most reactors in Europe are state-owned, limiting the potential impact on investors.

The decline in nuclear capacity in the United States is less severe than in the European Union as most of the fleet has received 20-year life extensions. Still, nuclear capacity in the United States would fall by half over the next twenty years. The publicly traded utilities most exposed to this decline are Exelon, who owns 21 reactors, Entergy, who owns eight reactors, and Duke Energy, who owns 11. Several utilities own two or more reactors such as Dominion, Pacific Gas, and Electric, MidAmerica, and NextEra. Utility investors should be aware that extending the life of a nuclear reactor is often the cheapest route towards maintaining current production levels. A lifetime extension for a reactor typically requires a capital investment of between $500 million to $1 billion but results in operations that produce electricity at a levelized cost of between $40 and $55 per MWh, making it competitive with most new-build generation projects.

A sharp reduction in nuclear power output in advanced economies may increase the use of natural gas and defer the retirement of coal power. Estimates suggest that coal generation may increase by 4% and natural gas generation by 7%. If true, the incremental CO2 emissions between 2020 and 2040 would be equivalent to the CO2 emissions from China's entire power sector in 2018. To fill the capacity gap in a nuclear fad scenario, $210 billion of new investment in power plants and $120 billion in grid connections would be required. This is $340 billion in new investment to fill a capacity gap that could be covered by spending $170 billion to extend the useful life of the nuclear fleet.

In addition to upfront capital costs, the ongoing costs of production may also prove more expensive.

The IEA estimates that the additional cost of supplying electricity in a nuclear fade environment would be $40 billion a year on top of the additional Capex, an additional expenditure mostly derived from the cost of fuel. This would translate into an average 3% increase on consumer's electricity bills.

The cumulative cost of supply would thus be more than $1 trillion higher should a nuclear fade occur then if it did not. This is $1 trillion that must be offset by higher electricity costs for consumers, an increase in debt for corporates or governments, and represents a significant use of capital over 20 years that could likely be spent better elsewhere.

The nuclear fade scenario also results in an acceleration of the transition away from dispatchable electricity. This would occur simultaneously with our need to increase dispatchable electricity as renewable capacity increases and puts downward pressure on system reliability.

Battery storage will play a role in increasing the flexibility of renewables, but there is little evidence to-date that current storage technology is cost competitive with incumbent generation. In the interim, the result is that natural gas generation must increase. As Figure 2 shows, the potential additional natural gas capacity may be significant.

See the article here:

The Role Of Nuclear Power In A Clean Energy System - Seeking Alpha

Posted in Life Extension | Comments Off on The Role Of Nuclear Power In A Clean Energy System – Seeking Alpha

Six months to break the deadlock on life after Brexit – The Advocate

Posted: at 12:43 am

The U.K.'s decision to formally rule out any extension of the trade negotiations with the European Union means the two sides have just six months left to overcome their differences if they are to reach a deal. Here's a guide to the months ahead:

- June 12: No extension. Britain formally ruled out extending the 11-month transition period that began on Jan. 31. By the year-end, the two sides hope to reach an agreement on their future relationship. But after four rounds of negotiations, the talks are deadlocked, with the two sides at odds on issues such as the level playing field, the role of the European Court of Justice, and fisheries.

- June 15: Crunch talks. British Prime Minister Boris Johnson holds talks with European Commission President Ursula von der Leyen aimed at injecting momentum into the talks.

- June 18-19: European Council meeting of EU leaders.

- June 29-July 3: Back to the negotiating table. EU Chief Negotiator Michel Barnier and his British counterpart, David Frost, hold talks in Brussels. Like all the in-person meetings planned, it may be canceled because of the virus.

- June 30: Last chance. Final deadline for extending the transition period beyond Dec. 31.

- July 1: Soft deadlines. On the original timetable, the EU and U.K. should by now have reached an accord on fisheries, a precondition for a trade deal, as well as an accord on what access London's financial services firms will have to the single market after the year-end.

- July 6: The chief negotiators and their teams hold specialized discussions.

- July 13: The chief negotiators and their teams hold specialized discussions.

- July 20-24: Fifth round of talks scheduled to take place in London.

- July 27: The chief negotiators and their teams hold specialized discussions.

- Aug. 17-21: Sixth round of talks scheduled to take place in Brussels.

- Sept. 13: Extraordinary meeting of EU leaders in Leipzig, Germany.

- Oct. 15-16: EU leaders meet in Brussels. They will want any agreement to be nailed down by now to allow time in case individual member states have to ratify it -- but if Brexit negotiations have taught us one thing, it is that seemingly immovable deadlines can be moved.

- Dec. 10-11: EU leaders meet in Brussels.

- Dec. 31: End of transition period. If the two sides haven't signed a trade deal by now, Britain will default to trading on World Trade Organization terms. Tariffs and quotas would be imposed, and customs checks would be reintroduced.

See original here:

Six months to break the deadlock on life after Brexit - The Advocate

Posted in Life Extension | Comments Off on Six months to break the deadlock on life after Brexit – The Advocate

Nukes in Space: the Extinction Rebellion Yet to Be – CounterPunch.org – CounterPunch

Posted: at 12:43 am

Drawing by Nathaniel St. Clair

An article published in the Proceedings of the National Academy of Sciences recently argued that more species are going extinct due to human activity than occurred 66 million years ago, when an asteroid or similar hit the Earth.

Much less discussed is US President Donald Trumps (read: the military-industrial-complexs) Space Force, which Trump again championed at a recent address to the Kennedy Space Center, Florida. Space domination is Americas destiny, he told the audience. Referring to the protests that broke out across the US and the world, triggered by the slow suffocation on camera by a white cop of the unarmed, handcuffed black man, George Floyd, Trump said: I will not allow angry mobs to dominateunless they are angry mobs of police.

But what about calm mobs? The mob of military corporatists setting US weapons policy is calmly seeking to dominate space and thus the world. Trump went on to say: we will ensure a future of American dominance in space. This comes at a time when the US taxpayer is predicted to spend nearly half a trillion dollars over the next decade upgrading Americas aging nuclear weapons. The Space Force is integrating in various waystracking, surveillance, sensingwith the triad of nukes on land, in the air, and at sea.

PAVING THE WAY

In January 2017, the newly-unelected President Trump (he lost the popular vote by 2.9m), ordered the Department of Defense to conduct a Nuclear Posture Review. The document published a year later makes clear that the US possesses nuclear weapons, in part, so that our diplomats continue to speak from a position of strength on matters of war and peace. The Nuclear Posture Review cites Russia as the evil menace against which the US must defend by renewing its nuclear stockpiles.

But a Congressional Research Service report cites the view of US nuclear strategists who think that Russia has adopted an escalate to de-escalate strategy, where it might threaten to use nuclear weapons if it were losing a conflict with a NATO member, in an effort to convince the United States and its NATO allies to withdraw from the conflict. It notes that Russias modernization program began in the early-2000s. We might add that this was a couple of years after the US committed itself Full Spectrum Dominance of land, sea, air, and space. It was also around the time that the Bush II administration (2001-2009, which also lost the popular vote by half a million) pulled out of the Anti-Ballistic Missile Treaty 1972.

Arms Control Today reports that Trumps withdrawal from the Intermediate-Range Nuclear Forces (INF) Treaty 1987 leaves just the 2010 New Strategic Arms Reduction Treaty (New START) in place to limit U.S. and Russian nuclear weapons deployments. It notes that START 2010 is due to expire in February 2021. Moscow professed to want to negotiate instead of having the US simply withdraw. It then reiterated Russias commitments to match any US modernization and expansion of nuclear weapons. This is great for the US and Russian arms industries, but not so good for the prospects of human survival.

Part of the reason for withdrawing from the INF, according to US Defense Secretary Mark Esper, is to develop weapons to threaten China; though, of course, Esper puts it in different words, speaking instead of how great the development of an intermediate-range conventional weapon would be to the [Pacific Command] theater.

NUKES IN SPACE

On February 4th-5th, the Air Force Global Strike Command and 30th Space Wing test-launched the nuclear-capable Minuteman III intercontinental ballistic missile. The Space Force describes the ICBM as a unique portion of the Air Force Global Strike Command (AFGSC) nuclear enterprise.

First deployed in 1979, the W78 nuclear warhead is being renewed at a cost to US taxpayers of $8.6 billion. The renewal program began under Obama in 2010. It is scheduled for deployment in 2030 and will be renamed W78-1. The W78-1 is designed to be carried by the Minuteman III ICBM, recently tested by the AFGSC in collaboration with the Space Force and 30th Space Wing. Meanwhile, there are other ominous developments afoot.

In 2019, the Missile Defense Review advocated for placing interceptors, which can equally mean first-strike missiles, in space: Space-basing may increase the overall likelihood of successfully intercepting offensive missiles, the document claims. It can reduce the number of U.S. defensive interceptors required to do so, and potentially destroy offensive missiles over the attackers territory rather than the targeted state.

At the end of May 2020, Raytheons Missiles and Defense branch offered a job with secret clearance to engineers with expertise in radiation effects. The job calls for radiation hardening designs for missile defense interceptors. Interceptors are well-known by strategists to be, dual-use, potential first-strike weapons. We are executing programs and investing in systems designed to work in nuclear weapons and space environments, the document says. The job description mentions interceptors, which, if the authors of the Missile Defense Review have their way, could end up being based in space.

UPGRADES

Under the Stockpile Stewardship Program, Los Alamos no longer detonates nuclear weapons to test them, relying instead on non-nuclear tests and computer simulations. The Lab maintains old nukes via the Life Extension Program: ironic, given that the weapons do little other than threaten death. The LEP involves the analysis, replacement, and refurbishment of components.

The B61-3, -4, -7, and 11 nuclear gravity bombs are deployed to US and NATO bases. The B61 has been in service for 50 years, making it the oldest and most versatile weapon in the enduring U.S. stockpile. Designed and engineered at Los Alamos and Sandia National Laboratories, the Life Extension Program will keep the device in service for an additional 20 years. The B61-12 is being certified for delivery by current strategic and dual-capable aircraft, as well as future aircraft platforms. If we are interested in survival as a species, the dual-use element is problematic because Russian, Chinese, or other adversaries can never be sure whether the given bomber plane in or near their airspace is carrying nuclear weapons. This puts their militaries on high-alert and increases the likelihood of escalation through misunderstanding.

The W88 nuclear warheads Life Extension Program (LEP) started in 2012, again under Obama. The W88 came into service in 1988 with the Trident II D5 submarine-launched ballistic missile. The LEP will replace the arming, firing, and fusion system, and refreshes the weapons conventional high explosives, for safety reasons, of course. The LEP is compartmentalized across several labs. Los Alamos is in charge of W76-2 mod, a LEP for another Trident II D5 submarine-launched ballistic missile.

The W76-1 produces a high-yield and is, counterintuitively, safer for the world in some ways because enemies know that they will be obliterated and are therefore less likely to engage in the kind of warfighting that can lead to escalation. First produced in 2019 at the Pantex Plant in Amarillo, the W76-2 on the other hand produces a lower-yield explosion, blurring the lines between nuclear and non-nuclear war. Lower-yield weapons are more tempting for commanders and world leaders to use, but they risk retaliation from states with high-yield weapons and thus uncontrollable nuclear escalation. Los Alamos describes the W76-2 mod as a milestone in support of a national security initiative requested by the president in the 2018 Nuclear Posture Review.

The W80-1 is being extended at Lawrence Livermore via the W80-4, which will be ready by 2031. The scientists explain that the insensitive high explosive, triaminotrinitrobenzene (TATB), will be used for the warheads main charge. Engineers and chemists at Lawrence Livermore are helping to restart the TATB production process after 30 years of dormancy.

In April 2020, Raytheon won the contract to develop the Long Range Standoff Weapon (LRSO) for the US Air Force, on which the W80-4 will be placed. The LRSO will be capable of both nuclear and conventional strikes, says Defense News, which means that Russia and China will be on high-alert and prone to escalation in error, as the article later admits.

CONCLUSION: DIRECT THAT ENERGY

As Extinction Rebellion largely obeys COVID lockdown, Black Lives Matter and other solidarity groups take to the streets nationally and internationally. Militarized police push young, unarmed women to the ground, use their shields to knock over old men, and even fire their paint guns at people standing in their doorways filming. We have an out-of-control, predatory neoliberal economic system, a powder keg of 40 million unemployed Americans, a climate heating up by the day, causing wildfires in the Arctic, and a grim swing towards a new kind of buffoonish authoritarianism, with Bolsonaro in Brazil, BoJo the Clown in the UK, and the manic Narcissist-in-Chief in the White House running the most powerful nation on Earth.

As if all of this wasnt bad enough, world-threatening nukes are being modernized and incrementally based in space. We need a broad left coalition of Extinction Rebellion, Black Lives Matter, and a revived anti-nuclear campaign to team up with anti-space-weapons networks to, if not end this madness, at least mitigate it. Unless we succeed, we might not be here to rebel against our extinction.

See original here:

Nukes in Space: the Extinction Rebellion Yet to Be - CounterPunch.org - CounterPunch

Posted in Life Extension | Comments Off on Nukes in Space: the Extinction Rebellion Yet to Be – CounterPunch.org – CounterPunch